Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial.

被引：0
|
作者：
Soto, C. [1 ]
Torrecillas, L. [1 ]
Reyes, S. [1 ]
Ramirez, M. [1 ]
Perez, L. [1 ]
Cervantes, G. [1 ]
Gonzalez, F. [1 ]
Tellez, E. [1 ]
Cortes, P. [1 ]
Benitez, H. [1 ]
机构：
[1] ISSSTE, IMSS, Mexico City, DF, Mexico
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：20S / 20S
页数：1
相关论文
共 50 条
  • [1] Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from the Mexican Oncology Study Group.
    Torrecillas, L
    Soto, C
    Cervantes, G
    Benitez, H
    Acosta, A
    Cortes, P
    Gonzalez, F
    Zamora, R
    Rodriguez, G
    Silva, A
    Leoner, C
    Sauza, F
    Suarez, T
    Tokunaga, J
    Erazo, A
    Talavera, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S200 - S200
  • [2] Economic evaluation of sequential capecitabine (X) and taxanes vs. the combinations in patients (pts) with advanced/metastatic breast cancer (MBC): a Mexican Oncology Study Group (MOSG) trial.
    Reynoso, N
    Torrecillas, L
    Soto, C
    Reyes, S
    Perez-Michel, L
    Ramirez, M
    Cervantes, G
    Benitez, H
    Delgadillo, F
    Talavera, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S219 - S219
  • [3] Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study.
    Chan, S
    Romieu, G
    Huober, J
    Delozier, T
    Tubiana-Hulin, M
    Lluch, A
    Schneeweiss, A
    Llombart, A
    Carrasco, E
    Fumoleau, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 24S - 24S
  • [4] Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
    O'Shaughnessy, J
    Miles, D
    Vukelja, S
    Moiseyenko, V
    Ayoub, JP
    Cervantes, G
    Fumoleau, P
    Jones, S
    Lui, WY
    Mauriac, L
    Twelves, C
    Van Hazel, G
    Verma, S
    Leonard, R
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) : 2812 - 2823
  • [5] Efficacy of Capecitabine (X) monotherapy in anthracycline-pretreated metastatic breast cancer (MBC): preliminary results of phase II study(Experienced in single institution)
    Kurnianda, Johan
    Haryadi, Achmad
    Aryandono, Teguh
    ANNALS OF ONCOLOGY, 2004, 15 : 41 - 41
  • [6] Prognostic factors may aid treatment decisions when considering sequential or combined capecitabine (X)-based therapy for patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Mexican Oncology Study Group.
    Perez-Michel, L
    Ramirez, M
    Delgadillo, F
    Aguilar, C
    Tellez, E
    Palomo, A
    Silva, M
    Loredo, T
    Aldaco, F
    Torrecillas, L
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S200 - S201
  • [7] Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European Phase III trial
    Chan, S
    EJC SUPPLEMENTS, 2005, 3 (05): : 17 - 21
  • [8] Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes
    Vahdat, L. T.
    Thomas, E.
    Li, R.
    Jassem, J.
    Gomez, H.
    Chung, H.
    Peck, R.
    Mukhopadhyay, P.
    Klimovsky, J.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
    Li, Shufen
    Meng, Wenjing
    Zhang, Jibo
    Xie, Xiaojuan
    Hao, Chunfang
    Jia, Yongsheng
    Tong, Zhongsheng
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (05) : 1069 - 1076
  • [10] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
12345